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Abstract 
The aim of the present work was to study the effects of benfotiamine (S-benzoylthiamine O-monophosphate) 
upon glucose and lipid metabolism and gene expression in differentiated human skeletal muscle cells (myotubes) 
incubated for 4 days under normal (5.5 mM glucose) and hyperglycemic (20 mM glucose) conditions.  
Myotubes established from lean, healthy volunteers were treated with benfotiamine for 4 days. Glucose and lipid 
metabolism were studied with labeled precursors. Gene expression was measured using real-time polymerase 
chain reaction (qPCR) and microarray technology. 
Benfotiamine significantly increased glucose oxidation under normoglycemic (35% and 49% increase at 100 and 
200 µM benfotiamine, respectively) as well as hyperglycemic conditions (70% increase at 200 µM 
benfotiamine). Benfotiamine also increased glucose uptake. In comparison, thiamine (200 µM) increased overall 
glucose metabolism but did not change glucose oxidation. In contrast to glucose, mitochondrial lipid oxidation 
and overall lipid metabolism was unchanged by benfotiamine. The expression of NADPH oxidase 4 (NOX4) 
was significantly downregulated by benfotiamine treatment under both normo- and hyperglycemic conditions. 
Gene set enrichment analysis (GSEA) showed that befotiamine increased peroxisomal lipid oxidation and 
organelle (mitochondrial) membrane function. 
In conclusion, benfotiamine increases mitochondrial glucose oxidation in myotubes and down-regulates NOX4 
expression. These findings may be of relevance to type 2 diabetes where reversal of reduced glucose oxidation 
and mitochondrial capacity is a desirable goal. 
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Introduction 
Chronic hyperglycemia plays a major role in the development of vascular complications associated with both 
type 1 and 2 diabetes ( UK Prospective Diabetes Study (UKPDS) Group  1998; Brinchmann-Hansen et al. 1992;  
The Diabetes Control and Complications Trial Research Group  1993). These effects are believed to occur 
secondary to a build-up of glucose and glycolytic intermediates in the cytosol during bouts of hyperglycemia 
when intracellular glucose concentrations are abnormally increased (Brownlee 2001). Benfotiamine, a synthetic 
thiamine monophosphate analogue with improved intestinal absorption as compared to thiamine, prevents the 
adverse cellular changes associated with hyperglycemia and can prevent the development of diabetic retinopathy 
in mice (Balakumar et al. 2010; Hammes et al. 2003). These effects are believed to be mediated by increasing 
the activity of the thiamine-dependent and rate-limiting enzyme of the pentose phosphate
 
pathway (PPP), 
transketolase (TK), which shifts excess glycolytic metabolites away from central biochemical pathways of 
hyperglycemic damage (Hammes et al. 2003). It has also been shown that benfotiamine functions as a direct 
antioxidant in rodents which may contribute to its beneficial effect (Schmid et al. 2008). 
In addition to the harmful effects upon the vasculature, hyperglycaemia also contributes to insulin 
resistance in skeletal muscle (Richter et al. 1988). We have previously shown that myotubes exposed to chronic 
hyperglycemia have increased lipogenesis and intramyocellular triacylglycerol (IMTG) accumulation (Aas et al. 
2004). The mechanisms by which these effects occur are complex and remain unknown, but might involve 
mitochondrial dysfunction (Aas et al. 2011). It has been suggested that mitochondrial dysfunction is integral in 
the pathophysiology of insulin resistance and that its reversal may prevent the development of a number of 
metabolic sequelae associated with type 2 diabetes (Pagel-Langenickel et al. 2010).  
Oral benfotiamine results in a 10-40% increased incorporation of thiamine into liver and heart, whereas 
the incorporation is 5- to 25-fold higher into muscle and brain (Hilbig and Rahmann 1998). To improve our 
understanding of how benfotiamine affects glucose and lipid metabolism in cultured human skeletal muscle 
cells, we have therefore studied the effects of benfotiamine upon the metabolic fate of labeled glucose and fatty 
acids under conditions of normal glucose (5.5 mM) or chronic hyperglycemia (20 mM glucose) for 4 days. To 
assess whether metabolic changes were associated with changes in gene expression, we also isolated RNA and 
measured gene expression using real-time polymerase chain reaction (qPCR) and human gene expression 
microarrays.  
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Materials and methods  
Dulbecco’s Modified Eagle’s Medium low glucose (DMEM), L-glutamine, penicillin/streptomycin (10,000 
IE/10 mg/ml), HEPES, amphotericin B and L-carnitine were from Sigma-Aldrich, St.Louis, MO, US. Foetal calf 
serum (FCS), Dulbecco’s Phosphate Buffered Saline (DPBS) and trypsin/EDTA (0.05%) were from 
Gibco/Invitrogen, Grand Island, NY, USA. Ultroser G was from Pall Corporation, St-Germain-en-Laye Cedex, 
France. D-[1-14C]glucose (54 mCi/mmol), [14C]deoxy-D-glucose (287 mCi/mmol) and [1-14C]oleic acid (53 
mCi/mmol) were purchased from PerkinElmer, NEN, Boston, MA, USA. D-[14C(U)]glucose (5 mCi/mmol) were 
provided by American Radiolabeled Chemicals Inc., St. Louis, MO, USA. Insulin Actrapid® was from Novo 
Nordisk, Bagsvaerd, Denmark. Corning® CellBIND® microplates were from Corning B.V. Life Sciences, 
Schipol-Rijk, The Netherlands, 96-well UNIFILTER
®
 microplate from Whatman, Middlesex, UK, and 96-well 
Isoplate, ScintiPlate®-96 TC micoplates and the scintillation liquid Optiphase Supermix was from Perkin Elmer, 
Waltham, Massachusetts, USA. Bio-Rad Protein Assay Dye Reagent was from Bio-Rad Laboratories, NY, USA. 
Agilent Total RNA isolation kit was obtained from Agilent Technologies (Santa Clara, CA, USA). Illumina 
Human-6 Express BeadChips version 3 arrays were from Illumina (San Diego, CA, USA). 
 
Human skeletal muscle cell cultures  
Satellite cells were isolated from the M. obliquus internus abdominis of 6 healthy donors, age 38.8 (± 3.8) years, 
body mass index 22.1 (± 1.5) kg/m2, fasting glucose 5.0 (± 0.1) mM, insulin, plasma lipids and blood pressure 
within normal range and no family history of diabetes. The biopsies were obtained with informed consent and 
approval by the Regional Committee for Research Ethics, Oslo, Norway. The cells were cultured in DMEM (5.5 
mM glucose) with 2% FCS, 2% Ultroser G, L-glutamine (4 mM), penicillin/streptomycin (P/S) and amphotericin 
B until 70-80% confluent. Myoblast differentiation to myotubes was then induced by changing medium to 
DMEM (5.5 mM glucose) with 2% FCS, 25 pM insulin, L-glutamine (4 mM), P/S and amphotericin B. 
Experiments were performed after 8 days of differentiation, and preincubation with benfotiamine (100-200 µM) 
and/or hyperglycaemia (20 mM glucose) was started after 4 days.  
 
Substrate oxidation assay 
The muscle cells were cultured on 96-well CellBIND® microplates. Substrate, [U-14C]glucose (1 Ci/ml, 200 
µM) or [1-14C]oleic acid (1 Ci/ml, 100 µM), was given in DPBS with 10 mM HEPES (1 mM L-carnitine was 
also added with oleic acid as described previously (Aas et al. 2011)). A 96-well UNIFILTER® microplate was 
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 5 
mounted on top of the CellBIND® plate as described before (Wensaas et al. 2007), and the cells were incubated 
at 37°C for 4 h. The CO2 trapped in the filter was counted by liquid scintillation (MicroBeta
®, PerkinElmer). The 
remaining cell-associated radioactivity was also assessed by liquid scintillation, and the sum of CO2 and cell-
associated radioactivity was considered as total substrate utilization. Protein content in each well was determined 
(Bradford 1976), and the data are presented as CO2/mg protein or cell-associated radioactivity/mg protein. 
 
Scintillation proximity assay (SPA) 
Radiolabeled substrates taken up and accumulated by adherent cells were measured by SPA. The cells were 
grown and differentiated in 96 well ScintiPlate
®
-96 TC SPA plates. Measurements of [
14
C]deoxyglucose (1 
µCi/ml) uptake by SPA were performed in DMEM without phenol red (Sigma, MO, cat. no. D5030) with 
additional 100 µM glucose. Finally, the cells were washed 3 times with PBS and harvested with 0.1 M NaOH 
(200 µl/well). Protein was determined according to Bradford et al. (Bradford 1976). 
 
RNA isolation and microarray analysis 
Total RNA was prepared from primary myotubes from three donors using Agilent Total RNA isolation kit 
according to the supplier’s protocol (Agilent Technologies). RNA was used individually and RNA integrity was 
checked on chip analysis (Agilent 2100 bioanalyzer, Agilent Technologies, Santa Clara, CA, USA) according to 
the manufacturer's instructions. RNA was judged as suitable for array hybridization only if samples exhibited 
intact bands corresponding to the 18S and 28S ribosomal RNA subunits, and displayed no chromosomal peaks or 
RNA degradation products (RNA Integrity Number > 9.0). cRNA synthesis was performed using Illumina 
TotalPrep RNA Amplification (San Diego, CA, USA) according to the supplier’s protocol. Hybridization, 
washing, and scanning of Illumina Human-6 Express BeadChips version 3 arrays (San Diego, CA, USA) were 
according to standard Illumina protocols. Data extraction and quality control was performed using BeadStudio 
version 3.1.3.0 (Illumina) and the Gene Expression module 3.2.7. Arrays were normalized using quantile 
normalization, and expression estimates were calculated by GC robust multiarray average background 
adjustment. Gene set enrichment analysis (GSEA) (Subramanian et al. 2005) was used to test the specific 
hypothesis that groups of genes involved in glucose metabolism were changed during benfotiamine treatment. 
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Collections of gene sets were obtained using a gene set browser from the Broad Institute website 
http://www.broad.mit.edu/ gsea/ (Molecular Signatures Database v3.0). This browser searches a number of 
publicly available sources (e.g., Biocarta, Kegg) where genes are grouped if they belong to the same pathway 
and share ontology terms or clinical phenotypes. Thus, it is possible to define specific gene sets on the basis of a 
particular parameter of interest. Similar use of GSEA has been published earlier (Bohn et al. 2010). Gene set 
collections relevant for glucose and energy metabolism were obtained using the following keywords stepwise: 
”glucose”, ”insulin”, “energy”, ”lactate”, “mitochondria”, “transporter*” (*indicates truncated search), “lipid”, 
“DNA and Repair” and ”interleukin”. The larger, predefined gene set collections; C2, C3TFT and C5 from 
(www.broad.mit.edu/gsea/) were also tested. The C3 TFT (transcription factor targets) collection consists of 
gene sets that contain genes sharing a transcription factor-binding site defined in the TRANSFAC (version 7.4, 
http://www.gene-regulation.com/). The gene-sets in the C5 collection are grouped according to the gene 
ontology consortium. The C2 Gene sets are collected from various sources such as online pathway databases, 
publications in PubMed, and knowledge of domain experts. The benfotiamine treated samples were compared to 
untreated in paired GSEA analysis. GSEA was performed using J-express 2011 (www.molmine.com) according 
to the description on the J-express manual. The gene matrix was collapsed by selecting the maximum probes. 
Log fold change was used as the scoring method, the number of permutations was set to 1000 and gene sets with 
less than 10 genes or more than 500 genes were excluded from the analysis. False discovery rate (FDR) q values 
< 5% were used as criteria for significantly enriched gene sets. Minimum Information About a Microarray 
Experiment  (MIAME) standards (Brazma et al. 2001) were followed in the analysis and storage of microarray 
data. The raw data are available at the Gene Expression Omnibus (GEO) at http: www.ncbi.nlm.nih.gov/geo/ by 
accession number GSE31553. 
RNA isolation and analysis of gene expression by TaqMan
®
 qPCR 
Cells were harvested and total RNA was isolated by Agilent Total RNA isolation kit (Agilent Technologies, 
Santa Clara, CA, USA) according to the supplier’s total RNA isolation protocol. Total RNA was reverse-
transcribed with oligo primers using a Perkin-Elmer Thermal Cycler 9600 (25°C for 10 min, 37°C for 1 h 20 
min, and 85°C for 5 s) and a TaqMan reverse transcription reagents kit (High Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems, USA). Two micrograms of total RNA were added per 20 µL of total 
TaqMan reaction solution. Real-time PCR was performed using an ABI PRISMT 7000 Detection System 
(Applied Biosystems, USA). RNA expression was determined by SYBRT Green, and primers were designed 
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using Primer ExpressT (Applied Biosystems, USA). Each target gene was quantified in triplicate and carried out 
in a 25 μL reaction volume according to the supplier’s protocol. All assays were run for 40 cycles (95°C for 12 s 
followed by 60°C for 60 s). The housekeeping control genes GAPDH (FC -1.1, p=0.8 from microarray) and 
36B4 were both measured, and transcription levels are presented as averaged change relative to levels of 
GAPDH and 36B4.  Primer sequences: GAPDH (acc.no. NM_008084): F: CATGGCCTTCCGTGTTCCT, R: 
TGATGTCATCATACTTGGCAGGTT; 36B4 (acc.no. NM_007475): F: ATCTCCAGAGGCACCATTGAA, R: 
TCGCTGGCTCCCACCTT; NOX4 (acc.no.  NM_016931): F: TGGACCTTTGTGCCTGTACTGT; R: 
TGAGGATGACTTATGACCGAAA. 
 
Statistics  
All data are presented as mean ± SEM. Statistical comparison between different treatments was performed by 
linear mixed model (LMM) and Anova repeated measures using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). 
The parameter of interest was entered as the dependent variable, and pretreatment (with and without 
benfotiamine) and acute treatments were entered as fixed variables. Differences were considered statistically 
significant at p-values less than 0.05. All experiments were performed with at least triplicate observations, and 
replicate experiments were performed on cells from different donors. For microarray analysis, individual fold 
change (FC) for each donor was calculated by dividing the expression level after benfotiamine treatment on the 
expression level after control treatment. The individual fold change was then log2 transformed. Mean fold 
changes were calculated based on the log2-transformed individual fold changes, followed by identification of 
differentially expressed probe sets using Intensity-based moderated t-statistics (Sartor et al. 2006). P-values were 
corrected for multiple testing by using Benjamini and Hochberg’s false discovery rate (FDR) method (Benjamini 
and Hochberg 1995). Probe sets that satisfied the criterion of FDR < 10% (q-value < 0.1) and fold-change > 1.5 
or < -1.5, were considered to be significantly regulated.  
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Results 
Effects of incubation with benfotiamine on glucose metabolism 
Under normoglycemic conditions (NG, 5.5 mM glucose), basal [U-14C]glucose oxidation (CO2 formation) was 
significantly increased in myotubes after incubation with benfotiamine (increased by 35% [p=0.02] and 49% 
[p=0.003], after 100 and 200 µM benfotiamine for 4 days, respectively) (Fig. 1A).  We also measured glucose 
oxidation after incubation with lower concentrations of benfotiamine (1 and 10 µM) without observing any 
effect (Fig. 1D). Under hyperglycemic conditions (HG, 20 mM glucose for 4 days), glucose oxidation was 
significantly increased by 70% after exposure to 200 µM benfotiamine (p=0.01) (Fig. 1A). Total metabolized 
glucose (sum of CO2 formation and cell-associated glucose) was also significantly increased for 200 µM 
benfotiamine (p=0.001) (Fig. 1B) under NG conditions. Accordingly, we found a significant increase in 
fractional oxidation of [U-14C]glucose (CO2/sum of cell-associated plus CO2) after benfotiamine treatment (100 
and 200 µM) under both normoglycemic and hyperglycemic conditions (Fig. 1C). We found no significant 
changes in glycogen synthesis after incubation with benfotiamine (data not shown). Hyperglycemia decreased 
both glucose oxidation and total metabolized glucose (Fig. 1A and B) in agreement with earlier observations 
(Aas et al. 2011). 
 The effect of benfotiamine on glucose metabolism was compared with thiamine. As shown in Fig. 2 
both benfotiamine and thiamine increased total metabolized glucose at the highest concentration examined (200 
µM for 4 days), although the effect of benfotiamine was greater than for thiamine, 64% and 19%, respectively.  
There was no effect of thiamine on glucose oxidation (data not shown). 
To assess whether the increase in glucose utilisation was accompanied by an increase in glucose uptake, 
we measured cellular [14C]deoxyglucose uptake after incubation with benfotiamine. We found a small (17%) 
increase (p<0.001 overall effect) in glucose uptake after benfotiamine incubation for 4 days under NG conditions 
(Fig. 3).  
 
Effects of benfotiamine on fatty acid metabolism 
In contrast to the marked effects of benfotiamine upon glucose metabolism, benfotiamine had no significant 
effects upon [14C]oleic acid (OA) oxidation (CO2 formation) and overall lipid utilisation (CO2 formation plus 
cell-associated OA) when these processes were studied separately (Fig. 4A and B). However, in contrast to 
glucose, benfotiamine significantly decreased fractional OA oxidation (CO2/cell-associated OA plus CO2) at 
both 100 and 200 µM benfotiamine under NG conditions as compared to NG alone (p=0.002 and 0.007 
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 9 
respectively, Fig. 4C), and at 200 µM benfotiamine under HG conditions as compared to HG alone (p< 0.02, Fig. 
4C). HG treatment also decreased fractional oleic acid oxidation (Fig 4C).  
 
Effects of benfotiamine upon gene expression 
To examine whether the effects of benfotiamine treatment could be explained by changes in gene expression, 
microarray analysis was performed. Under normoglycemic conditions, a total of more than 100 genes were 
significantly upregulated after exposure to 200 µM benfotiamine, whereas more than 200 genes were 
downregulated (Tables 1 and 2 for the top 20 most down- and upregulated genes; all regulated genes 
supplementary tables s1 and s2). NADPH oxidase 4 (NOX4) and growth factor midkine (MDK) were 
significantly downregulated after benfotiamine treatment (-2.6 and -3.2 FC, respectively). Under hyperglycemic 
conditions, the expression of more than 50 and 100 genes were significantly up- and downregulated after 
benfotiamine treatment, respectively (Tables 1 and 2 for the top 20 most down- and upregulated genes, 
respectively). The expression of NOX4 and MDK were again found to be significantly downregulated by 
benfotiamine (-3.1 and -3.3 FC, respectively). NOX4 expression was verified by qPCR, confirming that 
benfotiamine had a marked downregulatory effect under both NG and HG conditions (Figure 5, p<0.05 overall 
effect). Contrastingly, SERPINB7 (a serine proteinase inhibitor) was significantly upregulated under both 
normo- and hyperglycaemic conditions (+3.4 and +2.3 FC, respectively). Most of the genes regulated by 
benfotiamine treatment were regulated both under NG and HG conditions. We did not find any significant 
changes in the expression of genes encoding for proteins directly involved in lipid or glucose metabolism after 
benfotiamine treatment.  
In addition, we have used GSEA to test the hypothesis that benfotiamine treatment of human myotubes can 
affect groups of genes associated with glucose metabolism when compared to control cells. A substantial number 
of relevant gene sets in the defined collections were significantly downregulated after benfotiamine treatment 
(table 3). Five gene sets defined by “energy”, one gene set defined by “lipid” and two gene sets defined by 
“transporter” were downregulated after exposure to benfotiamine. We found one upregulated gene set from the 
“glucose” collection. This gene set was associated with glucuronidation processes. Moreover, 11 gene sets from 
“lipid” collection were upregulated after benfotiamine treatment. Among these genes sets there were gene sets 
involved in peroxisomal fatty acid oxidation and organelle membrane function (including genes important for 
mitochondrial function). Lists of the differentially regulated gene sets and the genes that contributed to the 
regulation can be viewed in supplemental table s3.  
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Microarray data also showed that the level of muscle differentiation markers such as myogenin (-1.40 FC) and 
myoD (-1.07 FC) were not significantly affected by benfotiamine, indicating that this treatment does not 
interfere with the differentiation process of the myotubes.   
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Discussion 
Our findings are the first to show that benfotiamine increases glucose oxidation (CO2 formation) whilst down-
regulating NOX4 expression in cultured human myotubes. Benfotiamine also increased overall glucose 
utilization, which was also shown for thiamine. In contrast to glucose oxidation, we found no significant change 
in oxidation and overall utilization of oleic acid after incubation with benfotiamine.  
 Hammes et al. reported that there was no change in TCA cycle activity and that activation of transketolase 
(TK) was responsible for the effects of benfotiamine in cultured endothelial cells (Hammes et al. 2003). Our 
contrasting findings suggest that the increase in glucose oxidation that we observed in myotubes does not occur 
in endothelial cells. Preliminary data in human umbilical vein endothelial cells (HUVEC) supports this, as 
although we observed a marked increase in cell-associated glucose, we did not see the same marked increase in 
glucose oxidation as we saw in myotubes (data not shown).  
 It is unclear whether an increase in mitochondrial glucose oxidation, such as we observed, would have an 
adverse effect upon muscle cell function in vivo. In endothelial cells, it has been proposed that the adverse 
changes observed in endothelial cells exposed to hyperglycemia results from increased glycolytic flux causing an 
increase in electron donors (NADH and FADH2) into the electron transport chain and the subsequent generation 
of superoxide from the mitochondria (Brownlee 2005). However, other studies have indicated that an increase in 
pyruvate entering the mitochondria is beneficial as this increases the NAD/NADH ratio and thereby reduces the 
intracellular redox potential (Tilton et al. 1992; Van den Enden et al. 1995). GSEA analysis did not show any 
effect of benfotiamine on pathways directly involved in glucose metabolism (e.g. glycolysis). However gene sets 
involved in peroxisomal lipid oxidation and organelle membrane function (including mitochondrial OXPHOS 
genes) were upregulated after benfotiamine treatment. 
 The marked downregulation of NADPH oxidase 4 (NOX4) we observed after incubation with 
benfotiamine, if also present in other cell types, may be a key mechanism by which this compound exerts its 
beneficial effects in animal models of diabetes. NOX4 is upregulated in response to hyperglycemia (Xia et al. 
2006), is a primary source of reactive oxygen species (Basuroy et al. 2009) and is highly expressed in kidney 
(Gorin et al. 2005) and vascular endothelial cells (Chen et al. 2008). Benfotiamine has previously been shown to 
prevent genomic damage to cells exposed to prooxidants in vitro (Schmid et al. 2008) and ex vivo (Schupp et al. 
2008). Inhibition of NOX upregulation has been shown to prevent the development of nephropathy in STZ-
induced diabetic rat model (Xu et al. 2009). Notably, we found that benfotiamine also downregulated NOX4 
expression under normoglycaemic conditions, suggesting that benfotiamine may have effects upon the 
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constitutive expression of NOX4 unrelated to ambient plasma glucose concentrations. The significant 
downregulation of growth factor midkine (MDK) we observed after benfotiamine treatment may also exert a 
beneficial effect since it has been shown to play a key role in the development of diabetic nephropathy in a STZ-
induced diabetic mouse model (Kosugi et al. 2006).  
Our finding that the serine proteinase inhibitor SERPINB7 was significantly upregulated by 
benfotiamine under both normo- and hyperglycaemic conditions was unexpected. Recent studies have suggested 
that upregulation of SERPINB7 expression in response to hyperglycemia increases mesangial matrix 
accumulation and accelerates diabetic nephropathy in mice (Miyata et al. 2002). This may be secondary to 
inhibition of plasmin and matrix metalloproteinase activity (Ohtomo et al. 2008). This finding does not concord 
with a previous study showing that benfotiamine actually protects against diabetic nephropathy in animal models 
(Babaei-Jadidi et al. 2003). The reasons for this discrepancy are unclear, but may be related to differences in 
myotubes as compared to mesangial cells where SERPINB7 is predominantly expressed.  
In addition to increasing TK activity, it has previously been found that benfotiamine increases the 
expression of TK in renal glomeruli (Loew 1996). However, we did not find any change in the gene expression 
of TK in human myotubes using microarray. In addition, we did not find any significant changes in genes 
encoding enzymes involved in glycolysis and/or the TCA cycle that might suggest that the increased oxidation 
we observed may be secondary to changes in enzyme activity rather than gene expression levels.  
Using benfotiamine in vitro differs from in vivo since most of the benfotiamine given orally is partially 
dephosporylated in the gut to benzoylthiamine. Due to the enhanced membrane permeability of benzoylthiamine, 
oral benfotiamine leads to higher plasma and intracellular concentrations of the active metabolite, thiamine 
diphosphate (TPP), than thiamine (Loew 1996). Although intact benfotiamine is also delivered to cells via the 
reduced folate carrier-1 (RFC-1) which is then de-benzoylated to thiamine monophosphate (TMP) by cellular 
and plasma esterases (Thornalley 2005), it is not superior to thiamine in increasing the intracellular 
concentrations of thiamine in vitro (Volvert et al. 2008). The exposure of cells in vivo to intact benfotiamine is 
minimal (peak plasma conc. approx. 10 nM in subjects taking 250 mg benfotiamine/day) as compared to the 
supra-pharmacological concentrations used in this study (100-200 M) (Ziems et al. 2000). Although doses as 
high as 900 mg benfotiamine per day have been used clinically (Alkhalaf et al. 2010), we must take into account 
the possibility that the effects we observed were associated with the high concentrations used, which might result 
in the generation of esterase-derived thiols at concentrations not observed in vivo. It is also possible that 
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benfotiamine, but not thiamine, induces spontaneous rearrangement of S-acylcysteine derivatives to N-
acylcysteine derivatives that affects pyrimidine synthesis and related signalling (Edwards et al. 1996).  
Interestingly, we also found an increase in glucose oxidation in cells exposed to normoglycemia in the 
presence of benfotiamine. The effects we observed are therefore not simply a result of benfotiamine abolishing 
the previously documented inhibitory effects of hyperglycemia upon glucose uptake in myotubes (Aas et al. 
2004). However, we also found that 200 µM benfotiamine was able to reverse the inhibitory effect of 
hyperglycemia upon glucose oxidation. We have previously shown that chronic hyperglycemia reduces insulin-
stimulated glucose uptake and increases triacylglycerol formation from labeled glucose (Aas et al. 2004). We 
assessed the effects of benfotiamine upon overall glucose uptake under normoglycemic conditions both with and 
without insulin, and only found a small (17%) but significant increase of benfotiamine. Although we cannot say 
whether this increased uptake preceded or was a result of the increase in glucose oxidation, this increase in 
uptake was relatively minor compared to the more pronounced increase in glucose oxidation (35-70%). This 
would suggest that the effects of benfotiamine upon glucose oxidation cannot be explained by an increased 
glucose uptake itself.  
The decrease we noted in fractional oleic acid oxidation may reflect the inverse reciprocal relationship 
between glucose and lipid oxidation. This finding also makes it unlikely that the increase we observed in glucose 
oxidation is a result of a benfotiamine-induced change in myotube differentiation. Additionally we found no 
changes in muscle differentiation markers such as myogenin and myoD. However, our finding that benfotiamine 
decreased fractional oleic acid oxidation whilst increasing fractional glucose oxidation suggests that 
benfotiamine may stimulate a preferential oxidation of glucose at the expense of fatty acids. This may be 
secondary to increased generation of pyruvate from glycolysis. GSEA analysis also suggested that fatty acids 
could be channelled to peroxisomes for oxidation after treatment with benfotiamine. 
Most previous research into the biochemical effects of benfotiamine have focused on cells, such as 
endothelial cells, susceptible to hyperglycaemic associated damage (Balakumar et al. 2010). The clinical 
implications of the results from the present study are that oral benfotiamine has marked metabolic effects upon 
cells i.e., skeletal muscle, other than those typically associated with diabetic microvascular complications. 
Whether our results can be extrapolated to the in vivo situation is not clear, as the marked effects we observed 
were achieved using supra-physiologic concentrations of benfotiamine. If such effects do occur in vivo, our 
results suggest that benfotiamine may not only be beneficial for microvascular complications associated with 
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type 1 diabetes, but could also be of relevance to type 2 diabetes and obesity where reversal of reduced 
mitochondrial capacity and decreased glucose oxidation is a desirable goal (Aas et al. 2011). 
In conclusion, our study has shown that benfotiamine, but not thiamine, causes a marked increase in 
mitochondrial glucose oxidation in human skeletal muscle cells. Our finding that benfotiamine also reduces 
NOX4 gene expression offers a new insight into the mechanism/s by which this substance exerts its effects upon 
the development of diabetic complications. These findings suggest that benfotiamine has a wider range of effects 
in different cell types of relevance to both type 1 and type 2 diabetes than has previously been recognised. 
 
 
 
 
 
 
Abbreviations: NAD: nicotinamide adenine dinucleotide, NADPH: nicotinamide adenine dinucleotide 
phosphate, NOX: Nicotinamide adenine dinucleotide phosphate oxidase, TK: transketolase, PPP: pentose 
phosphate pathway, PDH: pyruvate dehydrogenase, KDH: ketoglutarate dehydrogenase, TCA: tricarboxylic 
acid, IMTG: intramyocellular triacylglycerol, SPA: scintillation proximation assay, NG: normoglycemic, HG: 
hyperglycemic, MDK: growth factor midkine, TMP: thiamine monophosphate, TPP: thiamine diphosphate, 
RFC: reduced folate carrier, OXPHOS: oxidative phosphorylation. 
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Table 1. Genes downregulated by benfotiamine  
 
 
[20 genes with greatest fold-change (FC) decreased after benfotiamine treatment (200 µM, 4 days) as compared 
to cells not exposed to benfotiamine under NG conditions, with corresponding values under HG conditions], 
adjusted p-value < 0.1. *Adjusted p-value > 0.1. N = 3 in each group.
Symbol Acc Description FC NG FC HG 
LRRN1 NM_020873 leucine rich repeat neuronal 1 -3.97 -3.43 
RARRES1 NM_206963 retinoic acid receptor responder  
(tazarotene induced) 1 
-3.62 -2.50 
COMP NM_000095 cartilage oligomeric matrix protein -3.39 -4.48 
COL15A1 NM_001855 collagen. type XV, alpha 1 -3.29 -3.10 
SPRR2G NM_001014291 small proline-rich protein 2G -3.28 -2.85* 
MDK NM_001012333 midkine (neurite growth-promoting factor 2) -3.23 -3.34 
COL16A1 NM_001856 collagen. type XVI, alpha 1 -3.18 -3.05 
TYMP NM_001953 thymidine phosphorylase -2.89 -2.20* 
PACSIN1 NM_020804 protein kinase C and casein kinase  
substrate in neurons 1 
-2.89 -2.30 
MYOT NM_006790 myotilin -2.86 -2.40* 
FAM180B XM_001716425 family with sequence similarity 180,  
member B 
-2.81 -3.25 
FRAS1 NM_025074 Fraser syndrome 1 -2.75 -2.88 
MGC16121 XM_001128419 hypothetical protein MGC16121 -2.68 -1.45* 
MXRA5 NM_015419 matrix-remodelling associated 5 -2.67 -2.72 
SORBS2 NM_021069 sorbin and SH3 domain containing 2 -2.66 -2.96 
HES4 NM_021170 hairy and enhancer of split 4 (Drosophila) -2.57 -2.43 
NOX4 NM_016931 NADPH oxidase 4 -2.56 -3.07 
CTHRC1 NM_138455 collagen triple helix repeat containing 1 -2.54 -1.90 
CHN2 NM_004067 chimerin (chimaerin) 2 -2.53 -1.95* 
CIRBP NM_001280 cold inducible RNA binding protein -2.51 -1.94* 
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Table 2. Genes upregulated by benfotiamine 
 
Symbol Acc Description FC NG FC HG 
SERPINB7 NM_003784 serpin peptidase inhibitor, clade B (ovalbumin),  
member 7 
3.39 2.27 
MX1 NM_002462 myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (mouse) 
3.19 3.32* 
CPA4 NM_016352 carboxypeptidase A4 3.16 1.57* 
TM4SF4 NM_004617 transmembrane 4 L six family member 4 3.11 2.14* 
LCE3D NM_032563 late cornified envelope 3D 2.76 2.54 
IFI44L NM_006820 interferon-induced protein 44-like 2.62 2.54 
PSG4 NM_213633 pregnancy specific beta-1-glycoprotein 4 2.43 1.98 
TSGA10 NM_182911 testis specific, 10 2.38 2.55 
NRXN2 NM_138732 neurexin 2 2.32 1.95 
MT1G NM_005950 metallothionein 1G 2.32 1.44 
CCL26 NM_006072 chemokine (C-C motif) ligand 26 2.18 1.60* 
hCG_1815504 XM_498560 hCG1815504 2.15 1.85* 
BRE NM_199193 brain and reproductive organ-expressed  
(TNFRSF1A modulator) 
2.12 1.79 
PSG11 NM_002785 pregnancy specific beta-1-glycoprotein 11 2.11 1.42* 
TFPI NM_001032281 tissue factor pathway inhibitor  
(lipoprotein-associated coagulation inhibitor) 
2.10 1.40* 
EVI2A NM_001003927 ecotropic viral integration site 2A 2.10 1.69* 
ALDH3A1 NM_000691 aldehyde dehydrogenase 3 family. memberA1 2.09 2.13 
FGGY NM_001113411 FGGY carbohydrate kinase domain containing 2.02 1.95 
DEFB103B NM_001081551 defensin, beta 103B 2.01 1.27* 
IFI44 NM_006417 interferon-induced protein 44 1.98 2.07* 
 
[20 genes with greatest fold-change (FC) increased after benfotiamine treatment (200 µM, 4 days) as compared 
to cells not exposed to benfotiamine under NG conditions, with corresponding values under HG conditions], 
adjusted p-value < 0.1. *Adjusted p-value > 0.1. N = 3 in each group. 
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Table 3. Number of regulated gene sets comparing control and benfotiamine treatment within each group under 
normoglycemic (NG) conditions (paired GSEA analysis, score: log-fold change, FDR ≤ 5%).  
 
 
  
Gene set collections Number of gene sets  
in collection 
 
Control > benfotiamine 
(downregulated by treatment) 
 
Benfotiamine > control 
(upregulated by treatment) 
C5bp   753 1 0 
C3TFT  582 
 
5 0 
C2 846 2 7 
Energy  63 5 1 
Glucose 63 0 1 
Insulin  97 0 0 
Lipid 141 1 11 
DNA and repair 77 0 0 
Interleukin 133 1 0 
Lactate  5 0 0 
 
Mitochondria 29 0 0 
Transporter* 29 2 0 
 
A gene set browser provided by Broad institute at www.broad.mit.edu/gsea/ was used to obtain the stress- 
 
associated gene set collections. Detailed information regarding the regulated gene sets and leading edge genes  
 
are given in online supplementary table s3. *indicates that truncated search keyword was used to create the  
 
gene set collections. C2, C3TFT and C5 are pre-defined gene set collections.  N = 3 in each group. 
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Figure legends 
 
Figure 1. The effects of benfotiamine upon (A) [U-14C]glucose oxidation (CO2 formation),  (B) total metabolized 
glucose (sum of CO2 formation and cell-associated glucose) and (C) fractional oxidation of [U-
14C]glucose 
(CO2/ sum of cell-associated plus CO2) under NG (normoglycemic, 5.5 mM glucose) and HG (hyperglycemic, 
20 mM glucose) conditions. Myotubes were treated for 4 days in the absence or presence of benfotiamine (100 
and 200 µM) under NG and HG conditions. All data are normalized to normoglycemic control and presented as 
mean ± SEM (n = 5 for NG and n = 3 for HG, independent muscle cell donors). ap<0.05 vs. control myotubes not 
exposed to benfotiamine under NG condition; bp<0.05 vs. control myotubes not exposed to benfotiamine under 
HG condition (linear mixed model (LMM), SPSS). HG treatment significantly decreased glucose oxidation and 
total metabolized glucose (p<0.001 overall effect) (LMM). (D) Dose-response effects of benfotiamine upon  
[U-14C]glucose oxidation (CO2 formation) under NG conditions (mean ± SEM, n = 2). 
 
Figure 2. The effects of thiamine and benfotiamine upon total metabolized glucose (sum of CO2 formation and 
cell-associated glucose).  Myotubes were treated for 4 days with or without thiamine (200 µM) or benfotiamine 
(200 µM) under NG (5.5 mM glucose) condition. All data are normalized to control and presented as mean ± 
SEM (n = 3 independent muscle cell donors). ap<0.05 vs. control myotubes not exposed to the compounds; 
bp<0.05 vs. thiamine (LMM). 
  
Figure 3. The effects of benfotiamine upon [14C]deoxyglucose uptake in cells under NG (5.5 mM glucose) 
condition. Myotubes were treated for 4 days in the absence or presence of benfotiamine (200 µM) before the 
addition of colorless DMEM with 100 µM glucose and [14C]deoxy-D-glucose (1 µCi/ml). Data represent mean ± 
SEM from cells isolated from 3 individual donors. Benfotiamine significantly increased overall glucose uptake 
(p<0.001, Anova repeated measures).  
 
Figure 4. The effects of benfotiamine upon (A) [1-14C]oleic acid (OA) oxidation, (B) overall OA utilization (sum 
of CO2 formation and cell-associated OA) and (C) fractional oxidation of OA (CO2/(sum of cell-associated plus 
CO2)) of OA under NG (5.5 mM glucose) and HG (20 mM glucose) conditions. Myotubes were treated for 4 
days with or without benfotiamine (100 and 200 µM) under NG and HG conditions. All data are normalized to 
normoglycemic control cells and presented as mean ± SEM (n = 5 for NG and n = 6 for HG, independent muscle 
cell donors).  ap<0.05 vs. control myotubes not exposed to benfotiamine under NG condition; bp<0.05 vs. control 
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myotubes not exposed to benfotiamine under HG condition (LMM). HG treatment significantly decreased 
fractional oleic acid oxidation (p<0.01 overall effect) (LMM). 
 
Figure 5. Effects of benfotiamine upon expression of NADPH oxidase 4 (NOX4) mRNA measured by qPCR. 
Myotubes were treated for 4 days with or without benfotiamine (200 µM) under NG and HG conditions. All data 
presented as mean ± SEM (n = 3 independent muscle cell donors). p<0.05 overall effect of benfotiamine vs. 
control myotubes (LMM). 
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